Author

Simon Travis

EFFECT OF MIRIKIZUMAB ON BOWEL URGENCY CLINICALLY MEANINGFUL IMPROVEMENT AND REMISSION: RESULTS FROM THE PHASE 3 LUCENT INDUCTION AND MAINTENANCE STUDIES
EFFECT OF MIRIKIZUMAB ON BOWEL URGENCY CLINICALLY MEANINGFUL IMPROVEMENT AND REMISSION: RESULTS FROM THE PHASE 3 LUCENT INDUCTION AND MAINTENANCE STUDIES

BOWEL URGENCY COMMUNICATION GAP BETWEEN HEALTH CARE PROFESSIONALS AND PATIENTS WITH ULCERATIVE COLITIS IN THE US AND EUROPE: COMMUNICATING NEEDS AND FEATURES OF IBD EXPERIENCES (CONFIDE) SURVEY
BOWEL URGENCY COMMUNICATION GAP BETWEEN HEALTH CARE PROFESSIONALS AND PATIENTS WITH ULCERATIVE COLITIS IN THE US AND EUROPE: COMMUNICATING NEEDS AND FEATURES OF IBD EXPERIENCES (CONFIDE) SURVEY

BOWEL URGENCY COMMUNICATION GAP BETWEEN HEALTH CARE PROFESSIONALS AND PATIENTS WITH ULCERATIVE COLITIS IN THE US AND EUROPE: COMMUNICATING NEEDS AND FEATURES OF IBD EXPERIENCES (CONFIDE) SURVEY
BOWEL URGENCY COMMUNICATION GAP BETWEEN HEALTH CARE PROFESSIONALS AND PATIENTS WITH ULCERATIVE COLITIS IN THE US AND EUROPE: COMMUNICATING NEEDS AND FEATURES OF IBD EXPERIENCES (CONFIDE) SURVEY

Simon Travis  et al.

EFFECT OF MIRIKIZUMAB ON BOWEL URGENCY CLINICALLY MEANINGFUL IMPROVEMENT AND REMISSION: RESULTS FROM THE PHASE 3 LUCENT INDUCTION AND MAINTENANCE STUDIES
EFFECT OF MIRIKIZUMAB ON BOWEL URGENCY CLINICALLY MEANINGFUL IMPROVEMENT AND REMISSION: RESULTS FROM THE PHASE 3 LUCENT INDUCTION AND MAINTENANCE STUDIES

Simon Travis  et al.

EUROPEAN AND UNITED STATES PATIENT PERSPECTIVES ON THE IMPACT OF MODERATE TO SEVERE ULCERATIVE COLITIS ON SEXUAL ACTIVITY: COMMUNICATING NEEDS AND FEATURES OF IBD EXPERIENCES (CONFIDE) SURVEY
EUROPEAN AND UNITED STATES PATIENT PERSPECTIVES ON THE IMPACT OF MODERATE TO SEVERE ULCERATIVE COLITIS ON SEXUAL ACTIVITY: COMMUNICATING NEEDS AND FEATURES OF IBD EXPERIENCES (CONFIDE) SURVEY

Simon Travis  et al.

Evolving treatment goals and unmet needs in ulcerative colitis: how to address the gaps? (Takeda Pharmaceuticals International AG)
Evolving treatment goals and unmet needs in ulcerative colitis: how to address the gaps? (Takeda Pharmaceuticals International AG)

Simon Travis  et al.

EFFICACY AND SAFETY OF INTRAVENOUS VEDOLIZUMAB FOR TREATMENT OF CHRONIC POUCHITIS: RESULTS OF THE PHASE 4 EARNEST TRIAL
EFFICACY AND SAFETY OF INTRAVENOUS VEDOLIZUMAB FOR TREATMENT OF CHRONIC POUCHITIS: RESULTS OF THE PHASE 4 EARNEST TRIAL

EFFICACY AND SAFETY OF INTRAVENOUS VEDOLIZUMAB FOR TREATMENT OF CHRONIC POUCHITIS: RESULTS OF THE PHASE 4 EARNEST TRIAL
EFFICACY AND SAFETY OF INTRAVENOUS VEDOLIZUMAB FOR TREATMENT OF CHRONIC POUCHITIS: RESULTS OF THE PHASE 4 EARNEST TRIAL

Simon Travis  et al.

ONLINE EDUCATION SIGNIFICANTLY IMPROVES GASTROENTEROLOGISTS' KNOWLEDGE OF URGENCY AS A KEY CONCERN FOR PATIENTS WITH ULCERATIVE COLITIS
ONLINE EDUCATION SIGNIFICANTLY IMPROVES GASTROENTEROLOGISTS' KNOWLEDGE OF URGENCY AS A KEY CONCERN FOR PATIENTS WITH ULCERATIVE COLITIS

Simon Travis  et al.

PRACTICAL DEEP LEARNING TOOL FOR SCORING OF ULCERATIVE COLITIS DISEASE ACTIVITY IN CENTRAL READING
PRACTICAL DEEP LEARNING TOOL FOR SCORING OF ULCERATIVE COLITIS DISEASE ACTIVITY IN CENTRAL READING

Simon Travis  et al.

BIOMARKERS AND BOWEL URGENCY IN RESPONSE TO MIRIKIZUMAB FOR ULCERATIVE COLITIS
BIOMARKERS AND BOWEL URGENCY IN RESPONSE TO MIRIKIZUMAB FOR ULCERATIVE COLITIS

Simon Travis  et al.

THE ASSOCIATION OF ENDOSCOPIC AND HISTOLOGIC ENDPOINTS WITH FAECAL CALPROTECTIN AND C-REACTIVE PROTEIN IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH MIRIKIZUMAB
THE ASSOCIATION OF ENDOSCOPIC AND HISTOLOGIC ENDPOINTS WITH FAECAL CALPROTECTIN AND C-REACTIVE PROTEIN IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH MIRIKIZUMAB

Simon Travis  et al.

THE IMPACT OF BOWEL URGENCY ON THE LIVES OF PATIENTS WITH ULCERATIVE COLITIS IN THE US AND EUROPE: COMMUNICATING NEEDS AND FEATURES OF IBD EXPERIENCES (CONFIDE) SURVEY
THE IMPACT OF BOWEL URGENCY ON THE LIVES OF PATIENTS WITH ULCERATIVE COLITIS IN THE US AND EUROPE: COMMUNICATING NEEDS AND FEATURES OF IBD EXPERIENCES (CONFIDE) SURVEY

Simon Travis  et al.

VARICEAL VS NON-VARICEAL ACUTE UPPER GASTROINTESTINAL BLEEDING: OUTCOMES IN THE 2022 UK AUDIT
VARICEAL VS NON-VARICEAL ACUTE UPPER GASTROINTESTINAL BLEEDING: OUTCOMES IN THE 2022 UK AUDIT

Simon Travis  et al.

ABSENCE OF BOWEL URGENCY IS ASSOCIATED WITH IMPROVEMENTS IN CLINICAL OUTCOMES IN PATIENTS WITH ULCERATIVE COLITIS RECEIVING MIRIKIZUMAB
ABSENCE OF BOWEL URGENCY IS ASSOCIATED WITH IMPROVEMENTS IN CLINICAL OUTCOMES IN PATIENTS WITH ULCERATIVE COLITIS RECEIVING MIRIKIZUMAB

Simon Travis  et al.

MUCOSAL HEALING WITH VEDOLIZUMAB IN INFLAMMATORY BOWEL DISEASE: EVIDENCE FROM EARNEST, A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL IN CHRONIC POUCHITIS
MUCOSAL HEALING WITH VEDOLIZUMAB IN INFLAMMATORY BOWEL DISEASE: EVIDENCE FROM EARNEST, A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL IN CHRONIC POUCHITIS

Simon Travis  et al.

ACUTE UPPER GASTROINTESTINAL BLEEDING IN THE UK: PATIENT CHARACTERISTICS, DIAGNOSES, AND OUTCOMES IN THE 2022 UK AUDIT
ACUTE UPPER GASTROINTESTINAL BLEEDING IN THE UK: PATIENT CHARACTERISTICS, DIAGNOSES, AND OUTCOMES IN THE 2022 UK AUDIT

Simon Travis  et al.

A RANDOMISED CONTROLLED CLINICAL TRIAL OF AUTOLOGOUS STEM CELL TRANSPLANTATION (HSCT) IN PATIENTS WITH TREATMENT REFRACTORY CROHN’S DISEASE (LOW INTENSITY THERAPY EVALUATION): ASTICLITE
A RANDOMISED CONTROLLED CLINICAL TRIAL OF AUTOLOGOUS STEM CELL TRANSPLANTATION (HSCT) IN PATIENTS WITH TREATMENT REFRACTORY CROHN’S DISEASE (LOW INTENSITY THERAPY EVALUATION): ASTICLITE

Simon Travis  et al.

AI AUTOMATED WORKFLOW FOR IMPROVING DETECTION AND SCORING OF ULCERATIVE COLITIS DISEASE ACTIVITY UNDER MULTIPLE SCORING SYSTEMS
AI AUTOMATED WORKFLOW FOR IMPROVING DETECTION AND SCORING OF ULCERATIVE COLITIS DISEASE ACTIVITY UNDER MULTIPLE SCORING SYSTEMS

Simon Travis  et al.

Item 1 - 19 / 19
1